Key Facts

Two Wholly-Owned Product Candidates in Significant Diseases

Three Clinical Opportunities

HCV

ANA598: a Non-Nucleoside Polymerase Inhibitor.

ANA773: a TLR7 Agonist Prodrug.

Oncology

ANA773: a TLR7 Agonist Prodrug.

Clinical-Stage Development Focused Company

Phase I clinical trial for ANA598 opened in Q2 2008. Successful outcome of healthy volunteer study in Q3 2008. Dosing in HCV patients expected to begin in 4Q 2008. Viral load data expected Q1 2009.

Phase I clinical trial for ANA773 in HCV opened in Q3 2008. Dosing in HCV patients expected to begin in 4Q 2008. Viral load data expected Q2 2009.

Phase I clinical trial for ANA773 in oncology opened in Q4 2007.

Operations based in San Diego, California.

Core Expertise

Drug development and translational research in antivirals and oncology.